Effects of Vaginal Oxytocin Gel on Vaginal Cytologic Parameters in Postmenopausal Woman
Status:
Not yet recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
Vulvovaginal atrophy affects around 90% of postmenopausal women who may present with symptoms
such as dryness, irritation, itching, burning, and dyspareunia that negatively affect the
quality of life. Topical estrogen is recommended for the treatment of vulvovaginal atrophy in
postmenopausal women and the FDA approved it. But it may increase the risk of breast and
endometrial cancer. The oxytocin hormone also promotes positive social behavior, stress
regulation, and female sexual arousal. Many previous studies show that topical oxytocin is
useful for reducing vaginal atrophy in postmenopausal women.